Biotechnology

MABWELL-B

Mwim Biotech's Denosumab Injection Approved for New Indications Including Bone Metastasis

Mabwell Biologics Receives FDA Approval for 9MW5211 Clinical Trials

Mabwell Biologics' 9MW5211 Clinical Trial Application Approved by FDA

Mabwell Biopharma-B Plans to Apply for Registration of Up to 1 Billion Yuan Directed Debt Financing Instruments

MaiWei Biopharma Discloses Latest Clinical Trial Results for Novel ADC for Cervical Cancer Treatment

MABWELL-B released FY2026 Q1 earnings on April 28 After-Market (BJT), actual revenue HKD 144.66 M, actual EPS HKD -0.6915

Mabwell Biologics Submits IND for Global First-in-Class LILRB4/CD3 TCE Bispecific Antibody 6MW5311

MABWELL-B to Release FY2026 Q1 Earnings on April 29 After-Market (BJT)

MABWELL-B released FY2024 Q4 earnings on March 24 Post-Market (BJT), actual revenue HKD 62.43 M, actual EPS HKD -0.9231

MABWELL-B released FY2025 Annual Earnings on March 24 (BJT), actual revenue HKD 724.1 M (forecast HKD 788.99 M), actual EPS HKD -2.6558

MABWELL-B released FY2025 Q4 earnings on March 24 (BJT), actual revenue HKD 107.51 M, actual EPS HKD -1.0325

MABWELL-B released FY2024 Annual Earnings on March 24 (BJT), actual revenue HKD 216.26 M (forecast HKD 364.19 M), actual EPS HKD -2.8252

MABWELL-B released FY2025 Q3 earnings on October 30, 2025 (BJT), actual revenue HKD 507.96 M, actual EPS HKD -0.1278

MABWELL-B released FY2024 Q3 earnings on October 30, 2025 (BJT), actual revenue HKD 28.34 M, actual EPS HKD -0.6991

MABWELL-B released FY2024 9 Months earnings on October 30, 2025 (BJT), actual revenue HKD 153.1 M, actual EPS HKD -1.8971

MABWELL-B released FY2025 9 Months Earnings on October 30, 2025 (BJT), with actual revenue of HKD 617.64 M and actual EPS of HKD -1.621

MABWELL-B released FY2024 semi-annual earnings on August 29 (BJT), actual revenue HKD 124.67 M, actual EPS HKD -1.1978

2493.HK released FY2025 Semi-Annual Earnings on August 29 (BJT), actual revenue HKD 109.54 M, actual EPS HKD -1.4941

MABWELL-B released FY2024 Q2 earnings on August 29, 2025 (BJT), actual revenue HKD 51.55 M, actual EPS HKD -0.6452

MABWELL-B released FY2025 Q2 earnings on August 29 (BJT), actual revenue HKD 61.71 M, actual EPS HKD -0.7114

I.CENTURY HLDG

KOS TALENT GP

RIVERINE CHINA

NEW AMANTE

REDCO HEALTHY

C&N HOLDINGS

RICI HEALTH

XL2CSOPHYNIX

ZXZN QI-HOUSE

DIGIT HOLLYWOOD

688062

02493

Mabwell (Shanghai) Bioscience Co., Ltd. has received approval from China's National Medical Products Administration to expand its denosumab biosimilar, Maiweijian, to include bone metastases from solid tumors and multiple myeloma. This expansion enhances Mabwell's competitiveness in oncology supportive care. The company is also accelerating international commercialization, with approvals in Pakistan and successful inspections in Colombia, aiming to capitalize on global demand.

Tip Ranks

Mabwell

Mabwell Wins Wider China Indications for Denosumab Biosimilar as Global Push Accelerates

Mabwell has received FDA clearance for its IND application for 9MW5211, a novel antibody aimed at treating inflammatory bowel disease (IBD). This marks the world's first clinical-stage drug candidate targeting this condition. The antibody selectively depletes pathogenic immune cells, potentially improving patient outcomes. Clinical trial applications for multiple indications, including IBD and multiple sclerosis, are under review in China. Preclinical studies indicate significant therapeutic potential, and safety evaluations show a favorable profile. Mabwell aims to enhance treatment accessibility and effectiveness in autoimmune diseases.

prnewswire

20:00 ETWorld's First | Mabwell's 9MW5211 Receives FDA Clearance for Clinical Trial Application

Mabwell (Shanghai) Bioscience Co., Ltd. has received FDA clearance for a first-in-human trial of its antibody candidate 9MW5211, aimed at treating inflammatory bowel disease. The trial will assess safety and tolerability in healthy subjects. The drug targets pathogenic immune cells and has shown promising preclinical results. Mabwell is expanding its global presence in autoimmune therapies, despite the uncertainties of drug development. The success of 9MW5211 could lead to significant market opportunities and improved patient outcomes, although future approvals depend on trial results and regulatory decisions.

Mabwell Wins FDA Green Light for First-in-Human Trial of Novel Autoimmune Antibody 9MW5211

Mabwell (Shanghai) Bioscience Co., Ltd. has announced a shift to electronic corporate communications for non-registered shareholders, complying with Hong Kong Listing Rules. Future reports and documents will be available in English and Chinese on the company's website and the Hong Kong Stock Exchange platform, eliminating individual notifications. Shareholders preferring hard copies can request them, but requests will only be valid until the end of the next financial year. This move emphasizes a transition towards digital communications in the biopharmaceutical sector.

Mabwell Moves Non-Registered Shareholders to Digital Corporate Communications

Mabwell (Shanghai) Bioscience Co., Ltd. plans to issue targeted debt financing instruments of up to RMB 1 billion to optimize its capital structure. The bonds, with terms of up to three years, will be issued in the interbank bond market to institutional investors. Proceeds will be used for repaying liabilities, funding project construction, and replenishing working capital. The board has approved the proposal, pending shareholder approval and regulatory clearance. Mabwell focuses on developing innovative biologic therapies and is listed in Hong Kong.

Mabwell Plans Up to RMB 1 Billion Targeted Debt Issue to Reshape Capital Structure

MABWELL-B (2493.HK) is currently priced at HK$27.100, down -0.51% for the day, with a 5-minute intraday increase of over 3%, and a market capitalization of HKD 12.3 billion. The company focuses on the research and development of innovative drugs, with short-term capital driving the stock price up during the trading session. There have been no major announcements recently, and the fluctuations may be related to active trading and market interest in the innovative pipeline

Movers Alert

Maiwei Bio (2493.HK) Spikes on Short-Term Rally